President and CEO

Wes Kaupinen

Mr. Kaupinen brings more than 20 years of life sciences experience as an operating executive and a private and public market investor, including having worked closely with several companies that have secured FDA approvals for novel treatments for high unmet need diseases. Prior to Palvella, Mr. Kaupinen served as Senior Vice President of Corporate Development and Commercialization at Insmed (NASDAQ: INSM), a global commercial stage biopharmaceutical company focused on rare diseases. Previously, Mr. Kaupinen was a Principal at Quaker Partners, a life sciences venture capital firm with $700mm under management, where he worked on several public and private investments, including recruiting new leadership to Insmed to execute on a rare disease strategy. Mr. Kaupinen has served as a board director or observer for more than 10 companies. Mr. Kaupinen earned an M.B.A. from the Wharton School of the University of Pennsylvania, and a B.A. in Economics from the University of Virginia.